You have no items in your shopping cart.
Search results for: 'sars'
98.00%
138.33 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.75) Spike S1+S2 trimer (YP_009724390.1, with mutations T19I, L24del, P25del, P26del, A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) was expressed with bacteriophage T4 fibritin and a C-terminal polyhistidine tag followed by an AVI tag. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.75).The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. Predicted N terminal: Val 16
C-His-Avi
20 μg98.00%
136.19 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BQ.1.1) Spike S1+S2 (YP_009724390.1, with mutations T19I, 24-26del, A27S, 69-70del, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BQ.1.1). Predicted N terminal: Val 16
C-His
100 μg98.00%
136.18 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.4.6) Spike S1+S2 (YP_009724390.1, with mutations T19I, L24S, del25-27, del69-70, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N658S, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.4.6). Predicted N terminal: Val 16
C-His
100 μg98.00%
26.52 kDa (predicted); 33.2 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (C.36.3) Spike RBD (YP_009724390.1, with mutation R346S, L452R) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant C.36.3). Predicted N terminal: Arg 319
C-His
100 μg98.00%
26.71 kDa (predicted); 36.55 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529 sublineage BA.2). Predicted N terminal: Arg 319
C-His
100 μg98.00%
134.54 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.1.529) which emerged in the South Africa. Predicted N terminal: Val 16
C-His
100 μg98.00%
136.29 kDa (predicted)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (EG.5.1) Spike S1+S2 (YP_009724390.1, with mutations T19I, L24S, del25-27, Q52H, V83A, G142D, del144, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, F456L, N460K, S477N, T478K, E484A, F486P, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant EG.5.1). Predicted N terminal: Val 16
C-His
100 μg98.00%
25.36 kDa (predicted); 38.8 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 (BA.2.86) Spike RBD (YP_009724390.1, with mutation I332V, G339H, K356T, S371F, S373P, S375F, T376A, R403K, D405N, R408S, K417N, N440K, V445H, G446S, N450D, L452W, N460K, S477N, T478K, N481K, V483del, E484K, F486P, Q498R, N501Y, Y505H) (Arg319-Lys529) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.2.86). Predicted N terminal: Arg 319
C-His
100 μg98.00%
28.41 kDa (predicted); 37.65 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutations K417N, L452R, T478K) (Arg319-Phe541) was expressed with a C-terminal polyhistidine tag followed by an AVI tag. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed. The mutations were identified in the SARS-CoV-2 variant (known as variant (AY.1/AY.2)) which emerged in the India. Predicted N terminal: Arg 319
C-His-Avi
20 μg98.00%
25.20 kDa (predicted); 25.20 kDa (reducing condition, due to glycosylation)
SARS-CoV-2
A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1) (Arg319-Lys529) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Arg 319
C-His
100 μg
